

Case Study Outcome

Indication: Kidney Disease

Kidney disease patients face demanding care routines that make trial participation difficult. By delivering support at home through HTS, we eased that burden & improved access.

Here's what our team was able to achieve in this global Phase 3 study.

10	Countries across Europe,
	North America and Oceania

- 12+ Month treatment period
- Patients referred to Home Trial Support
- 1,685 Home Trial Support visits conducted during the study



Improving Access For Kidney Patients

Patients living with kidney disease often face complex, long-term treatment plans that can be physically and emotionally demanding. Frequent clinic visits for blood tests, monitoring, and medication adherence can place an added burden on already vulnerable individuals, many of whom may experience mobility issues, fatigue, or require caregiver support. These logistical and health-related barriers can lead to missed visits, increased dropout rates, and delayed trial progress.

Home Trial Support (HTS) offers a patient-centric solution by bringing clinical trial procedures - such as blood draws, vital sign monitoring, and investigational product delivery - directly into the patient's home. This approach minimizes the need for travel, supports better adherence to protocol requirements, and improves overall patient experience. For kidney disease patients, this flexibility not only reduces disruption to daily life but also encourages continued participation throughout long-term studies.


In this kidney disease trial, HTS proved critical to both recruitment and retention. Sites using HTS recruited twice as many patients per month as those that did not, as a result the recruitment period was shortened by three months. As the study progressed, more patients were referred to HTS to support ongoing treatment and reduce dropouts - demonstrating how this service enhances trial accessibility and continuity of care for a complex patient population.

Key Outcomes & Impact of HTS

- 20% of study patients used Home Trial Support
- · Recruitment period shortened by 3 months
- · Sites using HTS recruited twice as many patients per month as those that did not
- Ongoing referrals to HTS during treatment helped improve patient retention
- · Further recruitment gains were possible with broader HTS adoption

This study highlights how Home Trial Support improves trial accessibility, speeds up recruitment, and helps maintain patient engagement in complex, long-term studies by placing patient needs at the heart of trial delivery and reducing the burden of participation.

Recruitment period reduced by 3 months through Home Trial Support



oute. Initi

MRN's Experience In Genito Urinary System & Sex Hormones Clinical Trials

Our team has supported **Genito Urinary System & Sex Hormones** studies in **14 countries** for **13+ years**, providing
services such as blood draws and IMP
administration (Subcut Injection & Infusion)
and much more.

14 countries

supported with HTS services

8 trials

supported with HTS services

181 sites

trained for Home Trial Support

519 patients

referred to Home Trial Support

2,455 HTS

visits performed

Delivering Quality And Maintaining Patient Safety

MRN is a global leader in Home Trial Support (HTS) services, bringing clinical trials to patients' homes to remove participation barriers and enhance trial efficiency. By expanding the geographical reach of clinical trials, HTS improves accessibility and inclusivity while ensuring trial visits fit patients' schedules.

For patients, HTS eliminates challenges like mobility limitations, travel distance, and scheduling conflicts. For sponsors and sites, it accelerates recruitment, improves retention, and enhances compliance, leading to better data and faster trial completion. With 116,000+home trial visits across 99 countries and experience in 100+ indications, MRN delivers trials across all phases and therapeutic areas.

Our healthcare professionals conduct in-home procedures, from patient training and assessments to complex drug administration and direct data capture. While visits happen at home, the Principal Investigator (PI) retains full oversight, ensuring trial integrity and patient safety.

MRN upholds the highest standards in patient and data safety. Our healthcare professionals complete rigorous, protocol-specific training with 100% accuracy, and we maintain ISO27001 and ISO 9001:2015 accreditation for strict regulatory compliance. With a proven track record in safe, efficient, and patient-focused HTS, MRN is making clinical trials more accessible and inclusive worldwide.

Delivering Community-Based Trials

focused on patients, focused on results

With our Home Trial Support services, we remove participation barriers by bringing trials to patients where they live, creating convenience and comfort that results in **increased recruitment and retention**.





Our project management and visit delivery team have a strong understanding of **global regulations for in-home care** and are able to collaborate directly with the Sponsor and country managers to expand services, ensuring patients receive necessary home visits as their needs grow.



"We act as a single provider with global delivery. This means we can scale quickly and efficiently to deliver where patients live."

Stuart Redding, CEO, MRN



Our offices

- UK Medical Research Network Ltd Milton Keynes
- WSA Medical Research Network Inc. Deerfield IL
- Spain Medical Research Network Madrid
- Germany Medical Research Network Germany GmbH Stuttgart-Vaihingen
- Japan Medical Research Network Japan KK Tokyo
- France Medical Research Network, Lyon
- enquiries@themrn.co.uk
- www.themrn.io

